Panel Discusses the Evolution of Therapy for HER2-Positive Breast Cancer

A multistakeholder roundtable discussion, moderated by Maria Theodoulou, MD, of New York Oncology Hematology, focused on HER2-positive breast cancer diagnosis, treatment, and management. Dr. Theodoulou was joined by Andrew D. Seidman, MD, Melissa Carver, MSN, ARNP, AOCN, and Christine McGinn, MSN, APRN, ACNP-BC.

In this segment of the roundtable series, the panelists discuss how therapy for HER2-positive breast cancer has evolved, and if indefinite therapy is still needed for certain patients.

Advertisement

Latest News

Advertisement
Advertisement
Our Contributors

Expert Interviews

Conference Highlights

Ashley Mitchum-Chapman, BSN, RN, OCNConferences | March 27, 2024
Learn how a team implemented early chemotherapy education for novice nurses.
View More
Cecilia BrownConferences | March 22, 2024
There was a significant association between the intake of certain fatty acids and overall survival outcomes.
Cecilia BrownConferences | March 22, 2024
Amivantamab plus chemotherapy “significantly prolonged time to symptomatic progression” compared with chemotherapy alone.
Cecilia BrownConferences | March 20, 2024
Researchers evaluated the use of ctDNA next-generation sequencing panels that included NTRK gene fusions.

Network Websites